A recent retrospective study led by Dr. Marilyn J. Siegel and her team at the Washington University School of Medicine in St. Louis has shed light on a critical issue in cancer care: routine clinical reads are more prone to overdiagnosing progressive disease when compared to RECIST 1.1 interpretations. This discrepancy holds significant implications, potentially leading to the premature discontinuation of effective treatments for cancer clinical trial participants and patients under standard care.
In this study, mint Lesion software was utilized for the criteria-based reads, determining overall response assessments according to RECIST 1.1 criteria, and generating structured reports for the clinical trial's principal investigator.
To learn more about the study's insights into the discrepant assessments and the suggested steps for mitigating this issue, click here.
Study Discovers Overdiagnosis of Progressive Cancer in Routine Clinical Evaluations
Related Resources
Related Resources
4 Questions – 4 Answers // Imaging in Clinical Trials
Mint Medical, Inc. Vice President of Clinical Trials, Kelie Luby Discusses Advances in Imaging Analysis in Clinical Trials and What’s Next for Mint…
Joint partnership between Mint Medical and Siemens Healthineers syngo.via
Siemens Healthineers and Mint Medical joined forces to accelerate imaging and result reporting software availability in hospitals when and where it is…
Mint-Data for Personalized Medicine at Cancer Center in Tübingen/Germany
Compiling structured real-world-data from different medical disciplines, such as molecular genetics, laboratory medicine, pathology or radiology, to…